Proactive monitoring of drug-drug interactions between direct oral anticoagulants and small-molecule inhibitors in patients with non-small cell lung cancer.
Judith L GulikersLeila-Sophie OttenLizza E L HendriksKristien WinckersYvonne HenskensJenneke LeentjensMichel M van den HeuvelRob Ter HeineSander CroesBerber PietRobin M J M van GeelPublished in: British journal of cancer (2024)
Proactive monitoring showed that a substantial proportion of patients had DOAC concentrations outside the expected ranges. DOAC concentrations were successfully normalised after treatment modifications. These results highlight the importance of proactive monitoring of DOAC-SMI DDIs to improve treatment in patients with NSCLC.
Keyphrases
- direct oral anticoagulants
- venous thromboembolism
- atrial fibrillation
- small molecule
- end stage renal disease
- chronic kidney disease
- small cell lung cancer
- newly diagnosed
- ejection fraction
- prognostic factors
- emergency department
- combination therapy
- advanced non small cell lung cancer
- protein protein
- electronic health record